DIAGNOSTIC TEST 138
Vedolizumab
Diagnostic test for monitoring of Vedolizumab levels and control of Anti-Drug-Antibodies (ADA) against the drug.
Indication
Monitoring of Vedolizumab level and control of Anti-Drug Antibodies (ADA)
Sample material
Serum
- Minim. volume: 0,7 mL
Transport
- Within Sweden: room temperature
- International: room temperature
Method
- Drug concentration: ELISA
- Anti-Drug Antibodies (ADA): RIA
Result
Drug concentration is reported as µg/mL. At drug concentrations <1 μg/mL it is recommended to further test for ADA. ADA is reported as a concentration (AU/mL).
Interpretation
Vedolizumab acts as an α4β7-integrin inhibitor. Low or unmeasurable concentration of the biologic pharmaceutical is associated with poor clinical effect. One explanation can be that anti-drug antibodies (ADA) block the effect and enhance clearance of the drug.
Presence of drug in the test sample may prevent the detection of ADA. To avoid this, the sample should be drawn just before the next dosing of the drug (drug trough level).
Need pricing information?
How to order
This test is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. -
Prepare your samples
Serum: At least 0.7 mL serum (plain serum tubes without additives).
-
Send samples and request form
Within Sweden
Samples can be sent at room temperature to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Send samples cold to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-08-18
